Abstracts
We are delighted to announce that submissions are now open for the PaCCSC & CST Research Forum 2025.
We invite authors to submit abstracts for both oral and poster presentations within the 2025 theme, The science behind the art of care: Clinical trials in cancer symptoms and palliative care. Read more about the forum theme.
Key dates
Early bird registration open: 15 October 2024
Abstract submissions open: 15 October 2024
Early bird registrations close: 9 January 2025
Abstract submissions close: 31 January 2025
Forum registration
Abstract authors (poster and oral) must be registered to attend the forum and available to present on the nominated day and time, which will be confirmed in February 2025.
PaCCSC & CST members pay a discounted registration fee. Please go to the forum registration page for information about registration and ticket prices.
Questions
Please send questions about the abstract process by email to cst@uts.edu.au.
How to submit your abstract
Abstracts must be submitted using the online form accessible by the button below. Please select your preferred type of presentation or if you would like to be considered for both types:
- Oral presentation: Must be original research, including results from a clinical trial, substudy, or pipeline towards a clinical trial. Oral presentations will be allocated 15-minutes (10-minute presentation plus 5-minutes for Q&A)
- Poster presentation: must be in cancer symptom management or palliative care
Criteria for abstract for oral presentation
- Must be original research.
- Must include study results of a trial or trial substudy or pipeline towards a clinical trial.
- References are not required.
- Abstracts reporting on studies at a very early stage or study protocols will not be accepted.
- Drugs should be referred to by their generic name. The use of trade names should be avoided unless necessary.
- The main source of funding of a study should be indicated at the end of the abstract.
Criteria for abstract for poster presentation
- Must be original research.
- Must be A1 or A0 size
- The main source of funding of a study should be indicated at the end of the abstract.
- If a PaCCSC or CST endorsed study, please contact us to request the updated poster template.
Abstract structure and assessment criteria for oral presentation
Abstracts must be structured, and will be assessed, based on the following criteria:
- Abstracts must be no longer than 300 words and include the following sections: Title, Authors, Background and Aims, Methods, Results, Conclusion, Funding
- Background and aims: relevance of hypothesis, clearly stated aims.
- Quality of methods: sampling, data collection, analytical strategy; stringency of theoretical position, reference to relevant knowledge base etc.
- Relevance to palliative care/cancer symptoms and pipeline to trial or clinical trial: All abstracts should demonstrate relevance to some aspect of palliative care practice or cancer symptom management, policy or research work, or contribute to a relevant theoretical or methodological debate in these patient populations.
- Originality of research: the presentation of new data or new concepts. Stringency of arguments when repeating previous work.
- Clear presentation of results: data interpretation, statistical power, application to palliative care or cancer symptoms management, etc.
- Conclusions: supported by the data presented, quality of the interpretation of own work.
- Please proofread your abstract to ensure correct spelling and grammar.
Submission process
- You may wish to draft your submission in a Word document first so that you can copy and paste it into the online form.
- Click the link below to access and complete the online form.
- We will confirm via email that your submission has been received.
- Any changes after submission (for example withdrawal of abstract, change of presenting author etc.) should be emailed to cst@uts.edu.au, including complete contact information of any new presenters.
- After the review process, the abstracts will be allocated to the Forum program, and all corresponding authors will be emailed the review panel's decision by 10 February 2025.
